Genomic Clinical Trials and Predictive Medicine

Genomics is having a major impact on therapeutics development in medicine. This book contains up-to-date information on the use of genomics in the design and analysis of therapeutic clinical trials with a focus on novel approaches that provide a reliable basis for identifying what kinds of patients are likely to benefit from the test treatment. It is oriented to both statisticians and clinical investigators. For clinical investigators, it includes background information on clinical trial design and statistical analysis. For statisticians and others who want to go deeper, it covers state-of-the-art adaptive designs and the development and validation of probabilistic classifiers. The author describes the development and validation of prognostic and predictive biomarkers and their integration into clinical trials that establish their clinical utility for informing treatment decisions for future patients.

Dr. Richard M. Simon is chief of the Biometric Research Branch of the National Cancer Institute, where he is head statistician for the Division of Cancer Treatment and Diagnosis. He is the lead author of the textbook *Design and Analysis of DNA Microarray Experiments* and has more than 450 publications. Dr. Simon has been influential in promoting excellence in clinical trial design and analysis. He has served on the Oncologic Advisory Committee of the U.S. Food and Drug Administration and is a frequent advisor to government, academic, and industry organizations involved with developing improved treatments and diagnostics for patients with cancer. In 1998, Dr. Simon established the Molecular Statistics and Bioinformatics Section of the National Cancer Institute, a multidisciplinary group of scientists developing and applying methods for the application of genomics to cancer therapeutics. He is the architect of BRB-ArrayTools software for the analysis of microarray expression and copy number data.
Practical Guides to Biostatistics and Epidemiology

Series Advisors
Susan Ellenberg, University of Pennsylvania School of Medicine
Robert C. Elston, Case Western Reserve University School of Medicine
Brian Everitt, Institute for Psychiatry, King’s College London
Frank Harrell, Vanderbilt University Medical Center, Tennessee
Jos W. R. Twisk, VU University Medical Center, Amsterdam

This series of short and practical but authoritative books is for biomedical researchers, clinical investigators, public health researchers, epidemiologists, and nonacademic and consulting biostatisticians who work with data from biomedical and epidemiological and genetic studies. Some books explore a modern statistical method and its applications, others may focus on a particular disease or condition and the statistical techniques most commonly used in studying it.

The series is for people who use statistics to answer specific research questions. Books will explain the application of techniques, specifically the use of computational tools, and emphasize the interpretation of results, not the underlying mathematical and statistical theory.

Published in the Series:
Applied Multilevel Analysis, by Jos W. R. Twisk
Secondary Data Sources for Public Health, by Sarah Boslaugh
Survival Analysis for Epidemiologic and Medical Research, by Steve Selvin
Statistical Learning for Biomedical Data, by James D. Malley, Karen G. Malley, and Sinisa Pajevic
Measurement in Medicine, by Henrica C. W. de Vet, Caroline B. Terwee, Lidwine B. Mokkink, and Dirk L. Knol
Genomic Clinical Trials and Predictive Medicine

Richard M. Simon
National Cancer Institute
CAMBRIDGE UNIVERSITY PRESS
Cambridge, New York, Melbourne, Madrid, Cape Town,
Singapore, São Paulo, Delhi, Mexico City

Cambridge University Press
32 Avenue of the Americas, New York, NY 10013-2473, USA
www.cambridge.org
Information on this title: www.cambridge.org/9781107401358

© National Institutes of Health 2013
This is a work of the U.S. government and is not subject to copyright protection in the United States.

This publication is in copyright (except for the United States of America).
Subject to statutory exception and to the provisions of relevant collective licensing agreements,
no reproduction of any part may take place without the written permission of Cambridge University Press.

First published 2013

Printed in the United States of America

A catalog record for this publication is available from the British Library.

Library of Congress Cataloging in Publication Data
Simon, Richard M., 1943–
Genomic clinical trials and predictive medicine / Richard M. Simon.
p. ; cm. – (Practical guides to biostatistics and epidemiology)
Includes bibliographical references and index.


Additional resources for this publication at http://brb.nci.nih.gov.

Cambridge University Press has no responsibility for the persistence or accuracy of URLs for external or third-party Internet Web sites referred to in this publication and does not guarantee that any content on such Web sites is, or will remain, accurate or appropriate.
Contents

Acknowledgments                                      page ix
Introduction                                          xi

1 Clinical Trial Basics                                1

2 Actionable Prognostic Biomarkers                    7

3 Phase II Designs                                    25

4 Enrichment Designs                                 35

5 Including Both Test-Positive and Test-Negative Patients 45

6 Adaptive Threshold Design                          59

7 Multiple Predictive Biomarkers: Predictive Analysis of Clinical Trials 65

8 Prospective–Retrospective Design                   83

Appendix A. Statistics Background                     91

Appendix B. Prognostic Classifiers Based on High-Dimensional Data 105

References                                           129
Index                                                139
I would like to acknowledge many of the people who directly and indirectly made this book possible: Drs. Robert Wittes and James Doroshow for their friendship and support of my work; my sons Jonathan and Noah Simon for making my life rich and full of love; my past post-doctoral Fellows Drs. Yingdong Zhao, Michael Radmacher, Kevin Dobbin, Abubakar Maitournam, Annette Molinaro, Sudhir Varma, Wenyu Jiang, Jyothi Subramanian, Kyung-In Kim, and Stella Karuri for working with me on much of the material described here; my colleagues Drs. Ed Korn, Larry Rubinstein, Boris Freidlin, and Lisa McShane for freeing me to pursue the study of genomics in cancer therapeutics; and my mother Rose Lander Simon Aach, my sister Florine Simon Bender Marks, and my friend Dr. Joseph Slavin for their love and their courage. Finally, I would like to thank the many clinical and basic scientists and statisticians I have worked with and learned from and all the men and women who dedicate their lives to helping patients with cancer and other debilitating diseases.
Introduction

Genomics is having a major impact on therapeutics development in medicine. In oncology, the impact is particularly profound. Cancer is a set of diseases resulting from DNA alterations, and each tumor is almost unique with regard to the somatic alterations that it harbors. In fact, not only do any two tumors differ with regard to their DNA alterations but each tumor is composed of subclones of cells, and the subclones differ from each other with regard to their mutational spectrum. Although the discovery of these DNA changes provides a rich source of potential molecular targets, the development and evaluation of therapeutics based on re-regulating these targets poses profound challenges, many of which are the topic of this monograph.

Our focus will be heavily on oncology, where the personalization of therapy is primarily based on the tumor DNA genome that has undergone somatic alterations. The material here should be of value, however, in the study of other diseases for which the candidate characteristics for disease personalization are often based on germ line polymorphisms or phenotypic measures of disease heterogeneity.

The randomized clinical trial has been a fundamentally important contribution to medicine. Randomized clinical trials have permitted us to distinguish the minority of new regimens that are effective from the majority of proposed interventions that are ineffective, harmful, and expensive. The history of medicine contains many examples of harmful treatments that persisted for decades based on erroneous expert opinion. Clinical trials attempt to make the opinion of medical authorities evidence based. Of course, we all know that data can be as misleading as authorities, and so clinical trials are rigidly structured to avoid the bias and errors of many data analyses. As a result, however, clinical trials
tend to be rather crude tools for answering simple questions. One of the challenges is whether they can be adapted to the more complex questions involved in the personalization of therapeutics, while retaining the high level of reliability in the conclusions that we have come to expect from randomized clinical trials.

In addition to addressing the development of therapeutics, this monograph is about the development and evaluation of diagnostic tests for enabling the right drug to be used for the right patient. There is currently an enormous amount of confusion, hype, and misinformation published about personalized medicine biomarkers.

Although this monograph is not a primer on clinical trials, I have included an introductory chapter that may serve as a useful introduction for some readers and be skipped by others. I include an appendix that covers the basic statistical background needed for the material in this text for nonstatistical readers. The second chapter addresses biomarkers, prognostic classifiers, and the evaluation of diagnostic tests. The subsequent chapters describe designs and analysis strategies for the use of genomics in prospective clinical trials. Chapter 7 also includes material on the development and validation of multivariate predictive classifiers for identifying patients whose prognosis is better on a specified treatment than a control. Most of the analysis methods described in Chapter 7 and Appendix B are available in the BRB-ArrayTools software (Simon et al. 2007) available at http://brb.nci.nih.gov. Chapter 8 describes the prospective–retrospective approach to evaluate the medical utility of prognostic and predictive biomarkers based on previously conducted clinical trials. I also include an appendix on the development and validation of prognostic biomarkers using high-dimensional data such as gene expression profiles.

The target audience of the monograph includes statisticians, clinical investigators, and translational scientists. The focus is on new approaches to the design of clinical trials with prospectively specified analysis plans that provide a reliable basis for identifying what kinds of patients are likely to benefit from the test treatment. The focus is not on statistically complicated model-based analyses. There is abundant literature on post hoc analysis of clinical trials using complex statistical models. The problem is that the post hoc approach does not result in the kind of reliable
conclusion that we expect from phase III clinical trials, so those analyses are considered exploratory and hypothesis generating for future trials. Here we emphasize designing a clinical trial and prespecifying an analysis plan so that one obtains information about whether the test treatment has any benefit and, if so, whether a reliable classifier that characterizes the patients who are most likely to benefit from the test treatment can be obtained.

The book includes novel designs and novel approaches that have been developed in the past several years. Web-based programs are available at http://brb.nci.nih.gov for utilizing some of the designs. For some of the designs discussed, sufficient time has not passed for there to be published examples. These designs are currently of considerable interest in oncology drug development. I hope that the monograph contains accessible material of importance for readers of diverse backgrounds and that it can help in our efforts to develop more effective treatments for debilitating diseases.